Biomica VP R&D to Present at the Pharmabiotics 2023 Conference on March 21, 2023

Rhea-AI Summary

Biomica Ltd., a clinical-stage biopharmaceutical company and subsidiary of Evogene (NASDAQ: EVGN), announced that Dr. Shiri Meshner, VP of R&D, will present at the Pharmabiotics 2023 Conference in Lyon, France, on March 21-22, 2023. Dr. Meshner's presentation, titled Biomica's BMC128 - a Rationally Designed LBP Consortium's Journey to the Clinic, will occur on March 21 at 3:40 PM CET. Biomica's proprietary BMC128, consisting of four live bacterial strains, showed significant tumor volume reduction and improved survival compared to anti-PD-1 therapy in preclinical studies. Currently, BMC128 is undergoing a Phase 1 trial (NCT05354102) in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma.

REHOVOT, Israel, March 15, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that its VP R&D, Dr. Shiri Meshner, will be presenting at the Pharmabiotics 2023 Conference, 'The Future of Microbiome-based Medicines', taking place in Lyon, France from March 21-22, 2023.

Dr. Meshner will be presenting on March 21, at 3:40pm CET, in a presentation entitled, 'Biomica's BMC128 - a Rationally Designed LBP Consortium's Journey to the Clinic.'

Biomica's proprietary BMC128 is a rationally designed consortia of 4 live bacterial strains which demonstrated a significant reduction of cancer tumor volumes and increased survival in pre-clinical animal studies compared to anti-PD1 therapy alone.

BMC128 is currently being tested in a 12 patient Phase 1 open label study (ClinicalTrials.gov Identifier: NCT05354102) to primarily evaluate its safety and tolerability in combination with anti-PD-1 (Opdivo) in patients with either non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma (RCC), in patients whose cancers did not respond to treatment with an anti-PD-1 drug. The objectives in this Phase 1 trial will also explore efficacy variables.

Dr. Meshner will be available for one-on-one meetings with participants throughout the conference, and those interested should be in touch with her directly. 

About Biomica Ltd.:

Biomica is a clinical stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing MicroBoost AI tech-engine, licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN).

For more information about Biomica, please visit www.biomicamed.com.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN) (TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene's subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by AgPlenus, medical cannabis products by Canonic and castor varieties, for the biofuel and other industries, by Casterra. 

Investor Contact: 

Kenny Green
Email: kenny.green@evogene.com
Tel: +1 212 378 8040 

Dr. Shiri Meshner, PhD, VP of R&D
Email: shiri.meshner@biomicamed.com  

Logo: https://mma.prnewswire.com/media/1974949/Biomica.jpg 
Logo: https://mma.prnewswire.com/media/1947468/Evogene.jpg

 

View original content:https://www.prnewswire.com/news-releases/biomica-vp-rd-to-present-at-the-pharmabiotics-2023-conference-on-march-21-2023-301772684.html

SOURCE Biomica Ltd.

FAQ

What is Biomica presenting at the Pharmabiotics 2023 Conference?

Biomica is presenting on its product BMC128, a microbiome-based therapeutic.

When is Biomica's presentation at Pharmabiotics 2023?

Biomica's presentation is on March 21, 2023, at 3:40 PM CET.

What is the focus of Biomica's BMC128 in the clinical trial?

BMC128 aims to evaluate safety and tolerability in patients with NSCLC, melanoma, and RCC.

What were the results of BMC128 in preclinical studies?

BMC128 showed significant tumor volume reduction and increased survival compared to anti-PD-1 therapy.

What are the dates and location of the Pharmabiotics 2023 Conference?

The conference is in Lyon, France, from March 21-22, 2023.